Abstracts that do not adhere to the following important points will be rejected:
The title should not exceed 15 words.
The abstract should not exceed 250 words.
Please use authors’ initials and surnames only.
Qualifications should be omitted. Do not include references, tables or figures.
Please do not use block capitals.
Please find examples at the bottom of the page.
You may choose among three different abstract types:
> Oral Scientific Presentation
> Poster Scientific Presentation
> Poster Educational Presentation
Oral Scientific Presentation
The abstract should be separated into “Aim”, “Methods”, “Results” and “Conclusion”. The abstract limit is 250 words. Abstracts should not include promissory notes such as “We will provide additional data during our presentation.” Authors of accepted oral presentations will be invited for a presentation within the Scientific Paper Sessions. Presentation time will be 8 minutes with 2 minutes for Q&A (depending on the final program).
Poster Scientific Presentation
The abstract should be separated into “Aim”, “Methods”, “Results” and “Conclusion”. The abstract limit is 250 words.
Poster Educational Presentation
The abstract should be separated into “Learning Objectives”, “Content Organisation”, and “Conclusion”. The abstract limit is 250 words.
Abstracts selected for presentation will be published in the Proceedings of the 17th International Cancer Imaging, given to all delegates and faculty. A downloadable version of your submission will be made available to our membership on the members only area of our website, and be available on the Cancer Imaging open access website. Authors of selected abstracts will be notified after Friday 30th June 2017.
It will be obligatory for all scientific presenters to be members of ICIS at the time of presentation in Glasgow. The annual membership fee of €95 will be added to the scientific presenters’ fee at registration if current membership is not in place. Membership will run for one year from date of registration; all standard member benefits will apply.
Queries may be addressed to the ICIS Secretariat
Tel: +44 (0)20 7036 8805 or Email: firstname.lastname@example.org
Submission deadline: Monday 29th May 2017
EXAMPLE - POSTER EDUCATIONAL
Chemotherapy Induced Cardiomyopathy: An Overview, Imaging Features, and Future Prospective
Authors: Divito D., Bondin M., Kirschner S. K., Stojanovska J., Ibrahim E., Frank L.
To review the spectrum of imaging findings of chemotherapy- induced cardiomyopathy in correlation with most common cytotoxic drugs and regimens.
Cardio toxic effect of chemotherapy is a well-recognized problem in cancer patients. Cardio toxicity depends on multiple predisposing factors, specific components of the chemotherapy regimen, length of treatment, and dosage.
We will present the spectrum of most common cardiotoxic chemotherapy agents and their combinations, specific effects on the myocardium, and imaging features of cardiomyopathies induced by chemotherapy.
We will review pathophysiology of chemotherapy induced cardiomyopathy including:
- Dose dependent cardiomyopathy
- Predisposing conditions –diabetes, presence of coronary artery disease, age.
- Potential reversibility
We will discuss imaging characteristics of chemotherapy induced cardiomyopathy
- Imaging modalities ( Echocardiography, Cardiac MR, and MUGA)
- Importance of monitoring cardiac function during and after treatment
- Distribution of late Gadolinium enhancement (LGE)
- Emerging technologies for early diagnosis of cardiomyopathy in cancer patients
Chemotherapy induced cardiomyopathy is a common problem among cancer patients, increasing long term morbidity and mortality and often leading to disability. Patients receiving chemotherapy treatment, particularly cardio toxic agents, should be routinely assessed for cardiac function to diagnose cardiomyopathy during the early phase of treatment and to prevent development of irreversible heart failure.
EXAMPLE POSTER SCIENTIFIC
The Value of 68Ga-PSMA Enhanced MR-PET in Patients with Biochemical Recurrent Prostate Cancer
Authors: E. Rummeny, K. Holzapel, T. Maurer, G. Weirich, E. Gschwend, M. Eiber
Aim: In patients with prostate Cancer increased levels of PSMA can be measured. Recently a new tracer, 68Ga-PSMA, was developed as a specific marker for hybrid imaging (PET/CT, MR-PET). In this study we evaluated the accuracy of 68Ga-PSMA in patients with rising PSA after radical prosatectomy, so called „biochemical recurrent prostate cancer“ (BRPC).
Materials and Methods: A total of 322 patients with BRPC underwent a MR-PET examination (Siemens Biograph mMR) after injection of about 150 mBq 68Ga-PSMA. Images were evaluated in cosensus by one experienced nuclear medicine physician and one radiologist. Pelvine lymphnode dissection was performed in most of the patients according to a predefined template with 8 fields. Lymphnode involvement was evaluated according to a 5 point scale with a patient- and a field-based analysis. These findings were startified according to PSA-values.
Results: Four patients were excluded from the study for different reasons. Sensitivity for detction of recurrence was 95.7 % for PSA-values ≥ 2ng/ml, 81.4 % for PSA-values of 1-2 ng/ml, 76% for PSA-values 0.5-1 ng/ml, and 51% for PSA values ≤ 0.5 ng/ml. In comparison to the MR-images alone MR-PET was of superior diagnostic value.
Conclusions: MR-PET using 68Ga-PSMA is a sensitive and highly accurate technique for the diagnosis of biochemical reccurence of prostate cancer after radical prostatectomy. It yields high diagnostic performance at relatively low PCA-values.